Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | RP1 |
Synonyms | |
Therapy Description |
RP1 is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain, which potentially induces an anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RP1 | HSV-1 RP1 | RP1 is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain, which potentially induces an anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | Recruiting | USA | FRA | ESP | DEU | 1 |
NCT04050436 | Phase II | Cemiplimab + RP1 RP1 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 4 |